Anthim Market Report 2026

Anthim Market Overview

• The Anthim market growth in the historic period has been driven by bioterrorism preparedness initiatives, government funding for biodefense • Market expansion is supported by continued biodefense investment, rising focus on pandemic and biosecurity readiness • Growth Driver: Impact Of Rising Bacterial Disease Prevalence On The Growth Of The ANTHIM Market • North America was the largest region in 2025 and Asia Pacific is the fastest growing region.

What Is Covered Under Anthim Market?

Anthim is a monoclonal antibody used to treat inhalational anthrax caused by Bacillus anthracis infection. It works by binding to the anthrax toxin, preventing it from entering cells and causing damage. The main types of anthim are adult and children. Anthim (obiltoxaximab) is indicated for use in adults as part of the treatment regimen for inhalational anthrax caused by Bacillus anthracis. The incical indication involved are inhalational anthrax treatment, post-exposure prophylaxis (pep) for inhalational anthrax, use in pediatric and adult population. The various applications involved are hospital, drugs store, and other applications.

What Is The Anthim Market Growth Forecast?

The anthim market size is expected to see strong growth in the next few years. It will grow to $6.13 million in 2030 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to continued biodefense investment, rising focus on pandemic and biosecurity readiness, expansion of emergency response infrastructure, technological advances in antibody production, long term government procurement contracts. Major trends in the forecast period include increased stockpiling of anthrax countermeasures, growing government preparedness programs, rising use of monoclonal antibodies in biodefense, expansion of emergency response treatment protocols, enhanced focus on rapid deployment therapies.

Global Anthim Market Segmentation

1) By Type: Adult, Children 2) By Clinical Indications: Inhalational Anthrax Treatment, Post-Exposure Prophylaxis (PEP) For Inhalational Anthrax, Use In Pediatric And Adult Populations 3) By Application: Hospital, Drugs Store, Other Applications

What Are The Drivers Of The Anthim Market?

The rising prevalence of bacterial infections is expected to propel the growth of the anthim market going forward. Bacterial infections refer to diseases caused by harmful bacteria that invade the body, multiply, and produce toxins. The rise in bacterial infections stems from antibiotic overuse, global travel, urbanization, poor hygiene, and healthcare-associated infections. Anthim (obiltoxaximab) is used to treat anthrax, a bacterial infection caused by Bacillus anthracis, by neutralizing the anthrax toxin and preventing it from entering cells, thereby mitigating its harmful effects. For instance, in December 2023, according to report published by World Health Organization (WHO), a Switzerland-based health authority, suspected anthrax cases in Zambia rose from 42 between September 2022 and January 2023 to 684 by November 20, 2023, including four deaths (0.6% CFR), across 44 districts in nine of the country's ten provinces. Therefore, the rising prevalence of bacterial infections is driving the growth of the anthim industry.

Anthim Market Driver: Surge In Chronic Diseases Fueling The Growth Of The Market Due To Rising Demand For Long-Term Targeted Therapeutic Solutions The rising chronic disease is expected to propel the growth of the anthim market going forward. A chronic disease is a long-lasting health condition that progresses slowly and usually persists for years. Chronic diseases are increasing mainly due to unhealthy lifestyle habits such as poor diet and physical inactivity. Anthim is used to treat chronic conditions by providing targeted therapeutic effects that help reduce disease progression and improve long-term health outcomes. For instance, in June 2023, the Institute for Health Metrics and Evaluation, a US-based public health research institute, reported that over half a billion people globally were living with diabetes. This number is expected to more than double, reaching 1.3 billion people by 2050. Therefore, the rising chronic disease will drive the growth of the anthim market. The rising healthcare expenditure is expected to drive the growth of the anthim market going forward. Healthcare expenditure is the total spending on medical services, treatments, and healthcare resources, funded by governments, insurers, and individuals to ensure accessible and quality care. Healthcare expenditure is increasing mainly due to the growing burden of chronic and lifestyle-related diseases. Anthim benefits from rising healthcare expenditure as increased funding enables broader access to advanced therapies. For instance, In May 2024, according to the Office for National Statistics, a UK-based government department, reported that total healthcare expenditure saw a 5.6% increase in nominal terms from 2022 to 2023, marking a significant acceleration compared to the 0.9% growth observed in 2022. Therefore, the rising healthcare expenditure is driving the growth of the entecavir market.

Key Players In The Global Anthim Market

Major companies operating in the anthim market are Elusys Therapeutics Inc, Hikma Pharmaceuticals

Regional Insights

North America was the largest region in the anthim market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Anthim Market?

The anthim market consists of sales of monoclonal antibodies, injectable solutions and emergency response treatments. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Anthim Market Report 2026?

The anthim market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the anthim industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.